0001104659-23-082727.txt : 20230720
0001104659-23-082727.hdr.sgml : 20230720
20230720161728
ACCESSION NUMBER: 0001104659-23-082727
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230718
FILED AS OF DATE: 20230720
DATE AS OF CHANGE: 20230720
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Martins Eduardo Bruno
CENTRAL INDEX KEY: 0001670431
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41742
FILM NUMBER: 231099915
MAIL ADDRESS:
STREET 1: 350 CAMBRIDGE AVE, SUITE 350
CITY: PALO ALTO
STATE: CA
ZIP: 94306
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sagimet Biosciences Inc.
CENTRAL INDEX KEY: 0001400118
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 205991472
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 155 BOVET RD., SUITE 303
CITY: SAN MATEO
STATE: CA
ZIP: 94402
BUSINESS PHONE: (650) 561-8600
MAIL ADDRESS:
STREET 1: 155 BOVET RD., SUITE 303
CITY: SAN MATEO
STATE: CA
ZIP: 94402
FORMER COMPANY:
FORMER CONFORMED NAME: 3-V Biosciences, Inc.
DATE OF NAME CHANGE: 20070521
4
1
tm2321276-17_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2023-07-18
0
0001400118
Sagimet Biosciences Inc.
SGMT
0001670431
Martins Eduardo Bruno
SAGIMET BIOSCIENCES INC.
155 BOVET RD., SUITE 303
SAN MATEO
CA
94402
0
1
0
0
Chief Medical Officer
0
Stock Option (Right to Buy)
6.36
2023-07-18
4
D
0
198132
0
D
2031-02-18
Common Stock
198132
0
D
Stock Option (Right to Buy)
6.36
2023-07-18
4
A
0
198132
0
A
2031-02-18
Series A Common Stock
198132
198132
D
Stock Option (Right to Buy)
13.51
2023-07-18
4
D
0
44009
0
D
2033-04-19
Common Stock
44009
0
D
Stock Option (Right to Buy)
13.51
2023-07-18
4
A
0
44009
0
A
2033-04-19
Series A Common Stock
44009
44009
D
Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.
25% of the shares underlying this option vested and became exercisable on February 16, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
The shares underlying this option shall vest in forty-eight (48) equal monthly installments following April 20, 2023, subject to the Reporting Person's continued service on each such vesting date.
/s/ Dennis Hom, Attorney-in-Fact
2023-07-20